Diabetes patients with CKD on bardoxolone methyl show higher heart risk

01/2/2014 | Healio (free registration)

Data on 2,185 patients with type 2 diabetes and stage 4 chronic kidney disease revealed those who received bardoxolone methyl had a higher incidence of cardiovascular-related death, heart failure and hospitalization compared with those taking a placebo. The drug was also associated with increased incidence of nonfatal myocardial infarction and nonfatal stroke in patients, researchers reported in the New England Journal of Medicine.

View Full Article in:

Healio (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA